Wellcome Centre for Anti-Infectives Research 3 Year Report

Sharing our achievements

Wellcome Centre for Anti-Infectives Research 3rd year Report

Image on Front Cover is the ‘VEX’ed Trypanosome’ By Dr Joana Faria, a postdoc in the lab of Prof. David Horn. Joana studies the molecular mechanisms that underpin antigenic variation in African trypanosomes. The photo captures what happens to trypanosome variant surface glycoprotein (VSG) expression when you knockdown the expression of the genes VEX1 and VEX2 which sustain and coordinate VSG monoallelic expression. The image was a finalist in the Infectious Diseases Hub photography competition in 2019.

page 4

About WCAIR

page 6

News and Awards highlights

page 8

Setting our sights on infectious diseases

page 10

Research at WCAIR

page 11

Translational Biology

page 14

New challenges

page 16

Mode of Action

page 17

Enhancing the pipeline for target-based screening

page 18

Innovations in chemistry

page 20

The challenges of drug discovery for Chagas disease, part 1

page 21

The challenges of drug discovery for Chagas disease, part 2

page 22

Public Engagement

page 24

Training

page 27

WCAIR Management Board

page 29

Selected Publications

page 30

WCAIR Timeline

page 32

WCAIR Global Partners

page 34

WCAIR Advisory Boards

page 36

contents

Welcome

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 3

welcome

Welcome to our report on the Wellcome Centre for Anti-Infectives Research (WCAIR). Time has flown by, and as we have now completed three years, it’s time to share our achievements with you.

Although, COVID-19 induced lockdown has slowed us down recently, we have made a lot of progress across a broad range of activities including parasitology, drug discovery, training and public engagement. This report can only cover a high-level snapshot of our activities and progress so please don’t hesitate in making contact if you would like more information or wish to engage with us.

WCAIR's goal is to be at the cutting edge of drug discovery approaches, both now and in the future. To achieve this our vision must be far reaching and our horizon reaches out to 2030. It includes radically increasing the productivity of our projects, streamlining our approach. Working with our partners in this new way will allow us to deliver much needed new medicines for low- and middle-income countries.

Using a multi-disciplinary approach (e.g. biomedical, chemical, computing, engineering and mathematical sciences)

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 4

we are critically assessing and establishing new methodologies and technologies that can be implemented by a wide range of drug discovery groups.

We are leading on research to fill gaps currently hampering successful drug discovery. WCAIR supports a broad range of short- and longer-term projects seeking to develop new approaches. Many of these projects are identified by calls open to any member of the Centre and selected by a review process.

To accelerate the development of much needed new drugs, we need a greater understanding of the pathogens we target.

Our parasitology experts work with multiple global partners to achieve this.

Goals include a better understanding of their biology and potential weaknesses of the pathogens. This will allow us to identify potential drug targets through an improved ability to genetically manipulate them.

These genetic methods are also used by our world leading Mode of Action group to uncover the targets of multiple compound series, playing a major role in bringing together phenotypic- and target-based approaches across our drug discovery portfolio.

welcom

The goal of WCAIR is to position Dundee and others working on the major infectious diseases of low and middle income countries at the cutting-edge of drug discovery now and in the future.

We are developing improved in vitro and in vivo models of disease to better predict clinical efficacy and allow us to understand why compounds work or fail. This includes an enhanced understanding of pathogen distribution before and after drug treatment, and the ability of compounds to kill the parasites in clinically relevant states. These insights enable us to better focus our compound optimisation projects.

We are radically redesigning our drug discovery design-make-test cycle to accelerate projects to key milestones or project closure. WCAIR is integrating computational chemistry design with high throughput approaches to chemistry optimisation and synthesis.

This includes robotics to enable chemistry and assays, changes in strategy including testing unpurified compounds in both parasite- and target-based assays to reduce timescales and costs, and integration of the improved models of disease.

Finally, we are also addressing multiple other avenues to increase productivity.

This includes seeking to improve success rates of delivering proteins and systems suitable to support X-ray crystallography or cryo-EM studies to enable structure driven drug discovery, novel assays systems including high throughput X-ray fragment screening and mass spectrometry readouts, compound sets to expand available chemistry space, and ensuring we have state of the art equipment to underpin our work.

We have initiated a further review of key aspects of our work to ensure we are seeking solutions that will be relevant for many years to come.

Prof. Paul Wyatt, FRSE Director, WCAIR and Head of Drug Discovery Unit

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 5

about WCAIR

The vision of the Wellcome Centre for Anti-Infectives Research (WCAIR) is to support the 2012 London Declaration to eliminate Neglected Tropical Diseases (NTDs). We have created a world-leading hub for NTD drug discovery and are a collaborator of choice for academics, BioPharma and Product Development Partnerships (PDPs) in the translation of discovery science into drug candidates.

Parasite Discovery Biology

Mode of Action

Accelerating and innovating drug discovery research

Training and Capacity Building

Public Engagement

WCAIR is part of the Division of Biological Chemistry and Drug Discovery in the School of Life Sciences, University of Dundee. It encapsulates parasitology discovery biology, Mode of Action group and the Dundee Drug Discovery Unit.

Within WCAIR these groups work together to deliver innovative methods and technologies, training to scientists from disease endemic countries and engagement with local and global public communities.

Our Research goal is to position us and our partners at the cutting edge of drug discovery for major infectious diseases of low- and middle-income countries.

Together, we are developing new tools and methods to radically increase the rate of delivery and success of drug discovery projects. Creating a fundamentally redesigned and rigorous approach to drug discovery for these diseases.

Our Training goal is to create a skilled and knowledgeable cohort of drug discovery scientists within disease endemic countries. Empowering them to deliver medicines for their communities.

Our Public Engagement goal is to inform and inspire our publics about the many ways science fights poverty and disease. We want to reach a common understanding of each other’s needs so that we can co-create mutually beneficial outcomes.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 6

Over the next decade R & D at the Centre will generate a legacy of new therapeutics, new drug discovery approaches, novel targets and tool molecules that will impact and enrich the wider scientific, medical infectious diseases communities and patients.

WCAIR was created in April 2017 after an underpinning 5 year grant of £13.6million. At the same time Wellcome provided an additional £7.9 million to continue support of the kinetoplastid drug discovery programme for visceral leishmaniasis and Chagas disease. This programme is carried out with our partners GSK and DNDi. Wellcome also provided a £2.3 million strategic grant to the Mode of Action group. This will be renewed at the end of 2020. The major funders of the Centre’s TB, Malaria, Cryptosporidium and COVID-19/coronavirus drug discovery programmes are the Bill and Melinda Gates Foundation, Medicines for Malaria Venture, the Medical Research Council and the COVID-19 Therapeutics Accelerator (initiated by the Bill & Melinda Gates Foundation, Wellcome and Mastercard), respectively.

WCAIR in numbers 165 current members

Total number of people under the Centre funded through multiple sources, Feb 2020.

38 staff directly funded by Centre grant.

22 WCAIR trainees

Number of trainees completed a training period in Dundee as of February 2020.

86 papers

Total number of papers published by all WCAIR groups since April 2017 – March 2020.

£9.6 million

Average yearly income from all funders.

Wellcome funding is 67% of total.

£1 million internal funding for 15 projects

WCAIR funding allocated to internal innovation projects (consumables and postdoc salaries).

£1.2 million internal funding for equipment

WCAIR funding allocated to support equipment purchases to expand capabilities.

Visceral Leishmaniasis 1 clinical candidate 1 candidate to enter clinical development 2H2020

Clinical development candidates delivered by the DDU/GSK Portfolio Award, working through different novel mechanisms of action.

24 compound series molecular target identified

Compound series sourced globally, many identified targets are novel.

>40,000 engagements with public

Includes activities as part of Science Festivals and Careers Hive, visitors to LifeSpace exhibition, visitors to NMS exhibition, activities hosted at WCAIR e.g.

Medicine Maker badge and Dundee Rep.

1 International conference 160 attendees

A conference to share experiences and expertise around drug discovery across multiple diseases from bedside to bench.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 7

News and Awards Highlights Knighthood for Professor Mike Ferguson Professor Mike Ferguson, Regius Professor of Life Sciences at the University of Dundee and Deputy Chair of the Board of Wellcome Governors received a knighthood in the 2019 New Year’s Honours list. On receiving his award Prof. Ferguson said “I am thrilled to receive this great honour, but minded immediately that it recognises the efforts of many at the University of Dundee – my home for 30 years and an institution where collaboration and cooperation are truly valued, and where advancing knowledge into solutions is highly-prized. Together, we have managed to build in Dundee a truly world-class environment for science, and I feel very privileged to have been able to contribute to that. I am particularly grateful to my life- and science-partner, Dr Lucia Guther, and my family for support of every kind.”

Mattie Pawlowic wins inaugural BSP President’s Medal and Henry Dale fellowship Dr Mattie Christine Pawlowic has had a winning start to her career at WCAIR. At the end of 2018 Mattie won a prestigious Sir Henry Dale Fellowship from Wellcome and the Royal Society.

In April 2019 Dr Pawlowic won the inaugural British Society of Parasitology’s President’s medal. This will be awarded annually to an outstanding early-career researcher who has produced international-quality research and demonstrates the potential to become a world leader in parasitology. Dr Pawlowic’s research focuses on how the parasite Cryptosporidium protects itself from destruction, particularly a protective outer shell that makes it resistant to low-cost water treatment.

William Trager award for Professor David Horn WCAIR Deputy Director Prof. David Horn received the William Trager award at the 2019 Annual Meeting of the American Society of Tropical Medicine and Hygiene. The award recognised the breakthroughs Prof. Horn has made in understanding the basic biology of parasites which has unlocked new areas of research. The award committee hailed Professor Horn’s “transformative work, significant for both its fundamental and translational impact”.

The world leading research of David Horn and his group was also recognised through the receipt of a £2.1 million Wellcome Investigator award in 2019.

Promotions for leading WCAIR scientists David Gray, Head of Biology for the Drug Discovery Unit and academic lead for Public Engagement in WCAIR was promoted to a Personal Chair in October 2019. David will take the title Professor of Translational Biology.

Dr Susan Wyllie was promoted to Principal Investigator in July 2019. Dr Wyllie leads the Mode of Action group which undertakes drug target deconvolution studies with phenotypically active, anti-parasitic compounds. The group has identified the target of 24 compound series in the last 5 years.

Dr Manu De Ryker was promoted to Independent Investigator in 2020 Dr De Ryker is Head of Translational Parasitology and Portfolio Leader for Kinetoplastid Drug Discovery Programme and has recently received a MRC New Investigator Award to investigate the molecular determinants of the persister Trypanosoma Cruzi parasites seen in the Chagas disease assays he runs.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 8

Preclinical candidates for visceral leishmaniasis The kinetoplastid portfolio (funded by Wellcome in collaboration with GSK) have declared 2 pre-clinical candidates since 2018. The first candidate, GSK3186899/DDD853651, inhibits CRK12 a novel target in Leishmania. The compound is now progressing through clinical development. The 2nd pre-clinical candidate was shown to cure visceral leishmaniasis in a mouse model of the disease. The compound that targets the parasites proteasome has now completed pre-clinical development and will enter first-in-human studies by the end of 2020. The targets of both compounds were identified by the Mode of Action group.

GSK STOP award for Mode of Action group The Mode of Action group won the ‘Scientific Termination of Project’ Award in 2018.

The team showed that a compound series killed the parasites by a mechanism that had potential to damage human cells. Dr Susan Wyllie explained “Although it sounds negative, it’s a huge positive because identifying compound series that are not likely to be successful in the drug discovery process means we can divert much-needed resources into the development of more promising compounds.”

DDU Malaria team win MMV Project of the Year 2018 The Medicines for Malaria Venture prize is awarded annually to the scientific partners involved in that year’s most exciting project from the MMV portfolio. The 2018 prize was awarded to the DDU Malaria team led by Prof. Ian Gilbert, Prof. Kevin Read and Dr Beatriz Baragaña. The team are developing compounds to inhibit an enzyme involved in protein synthesis.

“The Dundee team was awarded MMV Project of the Year 2018 as their work with MMV really represents a step forward from business-as-usual drug discovery,” said Dr Timothy Wells, MMV’s Chief Scientific Officer. “Having a greater understanding of the structure of the drug target has been like shining a bright light on the work to optimise the drug series – it means we can be really precise as we improve the selectivity and potency of the compounds.”

WCAIR Public Engagement wins at School of Life Sciences awards WCAIR scientists taking part in public engagement activities have been recognised at the School of Life Sciences awards in 2018 and 2019. The 2018 prize for Engaged Researcher was jointly shared by Lesley-Anne Pearson and Lauren Webster.

The Project of the Year was ‘Kirsty’s project: Search for a new medicine’ a children’s book conceived by Suzanne Duce and Tracey Baylis and illustrated by Daisy MacGowan.

In 2019 the Project of the Year was awarded to the the WCAIR team who created the Medicine Maker badge for Girl Guides.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 9

Setting our sights on infectious diseases In May 2019 WCAIR hosted its first international conference, ‘Setting our sights on infectious diseases’, SOSID. The conference aimed to harness cross-disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate attrition rates for infectious diseases affecting low- and middle-income countries (LMIC).

Conference sessions spanned the whole pipeline from the initial start of a drug discovery programme through to clinical trials. We started with an introductory session on the current global disease situation and then worked backwards from clinical development, combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways to new start points and targets. Overall, the conference aimed to learn lessons from across different disease areas and between the preclinical and clinical phases, with the aim of exploring how we can improve and speed up the drug discovery, translational and clinical development processes.

We were keen to ensure that viewpoints of researchers from disease endemic countries were captured during conference discussions. We therefore raised sponsorship to support 19 travel bursaries for early career researchers from LMICs. Each bursary paid for registration, travel and accommodation.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 10

The WCAIR management thank the generosity of Medicines for Malaria Venture (MMV), the Bill and Melinda Gates Foundation, Novartis Institutes for Biomedical Research and Drugs for Neglected Diseases initiative (DNDi) for their support.

The 160 people attending the conference included participants from Africa, South America, Cuba, Europe, North America, Malaysia, India and Australia. Evaluation of the conference showed very positive feedback with 98% saying they would attend another WCAIR conference; 94% Agreed or strongly agreed they now have a better understanding of drug discovery for infectious diseases in LMICs; 92% Agree or Strongly Agree they now have new ideas to solve challenges they face in their own work; 90% Agree or Strongly Agree SOSID has allowed them to make new connections.

Ian Gilbert has coordinated a paper with contributions from all the conference speakers to capture the topics, learnings and discussions which took place. You can read the viewpoint paper in ACS Infectious Diseases, https://doi.org/10.1021/acsinfecdis.9b00371 We thank all our speakers and the Division of Biological Chemistry and Drug Discovery admin team for their contribution to a successful conference.

Research at WCAIR

Research at WCAIR is tackling a variety of gaps and issues to create impact across the whole of the drug discovery continuum. These include: Gaining a deeper understanding of parasite biology and mode of action of successful therapeutics.

Defining critical paths and assay cascades predictive of human efficacy.

Applying and integrating state-of-the-art approaches to compound design and synthesis.

Strategic research and technology implementation are designed, planned, coordinated and adjusted by the Director and WCAIR management team. This is augmented by supporting and developing internally peer-reviewed “bottom-up” ideas from WCAIR staff to capture innovation relevant to our mission and to encourage forward thinking in the team.

Strategic developments to date include: > Improving our ability to manipulate pathogens at a genome-wide scale (e.g. genome-wide under- and over-expression) or at a precision level (e.g. CRISPR genome editing). These tools help power all our parasitology research, improving our understanding of parasite biology, identifying potential weaknesses, and discovering new drug targets. > Applying these genetic and proteomic methods (via our cutting-edge Mode of Action group) to identify the modes of action of numerous in-house and collaborator compound series. This allows rational decisions on the progression of the drug-lead portfolio, ensuring individual targets are not over-represented and the transition of phenotypic projects into structure-enabled ones. > Developing advanced quantitative chemical proteomics for drug target deconvolution.

> Expanding our range of assays systems, including replacing in vitro reporter assays with a RapidFire® mass spectrometry-based high throughput compound screening system. > Enabling our structure-based drug discovery projects by introducing high throughput construct design and expression system testing, and by collaborating with Diamond, Oxford to establish and optimise X-ray fragment screening of thousands of crystal soaks. > Radically redesigning the compound design-make-test cycle to accelerate drug discovery projects to key milestones or project closure. For example, enabling better and quicker decision making for compound series, by integrating improved computational compound design with high throughput chemistry synthesis approaches (e.g. chemistry based on 384 micro-titre plate formats). This is enabled by robotics and testing these compounds unpurified in biochemical and parasite assays. > Developing better models of disease that predict animal model and clinical efficacy, allowing us to understand why compounds work and why they don’t. For example, for Chagas disease this includes developing an understanding of parasite distribution before and after drug treatment and the ability of compounds to kill them in clinically relevant states. The latter includes dormant/persister parasites that are more difficult to kill than replicating forms. These insights enable us to better focus our compound optimisation projects. > Introducing Cryptosporidiosis into our repertoire of biology and disease expertise. WCAIR co-funded with the University of Dundee some of the set-up costs to recruit Dr Mattie Pawlowic (now a Sir Henry Dale Fellow) to WCAIR. Further details of our research programmes are discussed on the following pages.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 11

Schematic showing where strategic and in-house ‘bottom up’ research is impacting the drug discovery process.

KEY TO PROJECTS

Parasitology

Gene manipulation

Assays

Structure based drug discovery

High throug expression a

High th of cryst Proximity labelling methods to model the Cryptosporidium inner oocyst wall

Pathogen Biology

High through usin

Target ID, Mode of Action

CRISPR/CAS9 gene editing for kinetoplastid parasites

RapidFire® high throughput mass spec assays

Overexpression library of P.knowlesi

WCAIR multi-omics hub

In vitro translation screening assay T.cr

In vitro drug combina screening platform

In silico prediction fragment binding affinities – QM, FMO ML methodologie

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 12

Parasite imaging

Chemistry

Computational

In silico virtual chemistry explosion

ghput protein cloning, test and small scale purification

roughput optimisation tallography conditions

hput scteening of fragments ng crystallography

Hit ID

s

Plate-based chemistry In silico design of: Chemistry routes, experiments

Relating NMR solution and X-ray binding conformations to improve compound

Synthetic methods to deliver chemical diversity Monomer sets for array chemistry, e.g. Ames negative amino-aromatics

Hits to Candidates

Compound Libraries Covalent Fragments Natural Products

n ruzi

Live imaging kill curve assay

ation m

Dynamic in vitro PK/PD model for intercellular parasites

of g and s

Flow chemistry

Whole body imaging of T.cruzi parasites

Gastroplus-PKPD in silico modelling

Biotransformation to deliver chemical diversity from fragments and hits

In silico prediction of fragment binding affinities

T.cruzi persister assays

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 13

Translational biology Learning from the parasites

It has become increasingly clear in recent years that the gene expression pathway from DNA to RNA to protein in trypanosomatids presents several excellent druggable targets.

These include targets involved in transcription (DNA to RNA), RNA processing, translation (RNA to protein) and protein turnover.

However, major unanswered questions remain in terms of druggable gene expression mechanisms in these parasites.

Unusually, almost every trypanosomatid gene is transcribed as part of a long multi-gene polycistron. Both RNA polymerase II or RNA polymerase I can transcribe these genes, and the RNAs are all trans-spliced prior to export from the nucleus and translation into protein.

The Horn group have recently focussed on investigating the mechanisms that allow trypanosomes to control differential gene expression in this context. Laura Jeacock’s work revealed a major role for DNA sequence composition, and therefore RNA sequence composition, known as codon-bias, in determining the efficiency of translation.

Anna Trenaman subsequently characterised an RNA-binding protein that increases the expression of a specific set of RNAs encoding proteins involved in energy metabolism in an essential cellular organelle known as the mitochondrion. Our work on the immune evasion strategy known as antigenic variation also bore fruit recently. Joana Faria characterised a protein complex that controls Variant Surface Glycoprotein (VSG) expression. The VEX-complex blocks the expression of all but one VSG per cell, a key virulence factor that makes the African trypanosome a very persistent parasite.

In current and future work, the group aim to identify further important RNA-binding proteins and the RNAs they control, to determine exactly how the VEX-complex controls singular VSG expression and antigenic variation and to determine how chromatin and chromosomal packaging control transcription and RNA processing.

The more we understand about these parasite gene expression mechanisms, the better placed we will be to facilitate this area of drug discovery.

The Ferguson group focus on uncovering the mysteries of trypanosome glycobiology.

In the past year, they have published as a pre-print the first report on the existence of an essential mitochondrial fucosyltransferase in Trypanosoma brucei that is conserved across all trypanosomatid parasites, but absent from all other species. This exciting discovery, and further unpublished work by Sam Duncan, challenges the canonical view of protein/lipid glycosylation being limited to the secretory pathway and cytoplasm, and provides a new parasite-specific potential drug target. The comparable enzyme in T. cruzi is now under investigation by Jose Paredes.

Lucia Guther has completed her identification of a novel glycosomal nucleotide sugar transporter (NST) and is working to determine its kinetic parameters. This is an entirely new class of NST, absent from mammals, necessary to move essential nucleotide sugars made (uniquely) inside the parasite glycosomes into the cytosol. The novelty and importance of this transporter suggests that it may be a good parasite-selective drug target.

As Sam continues our programme to define the specificities and functions of trypanosome glycosyltransferases by creating mutant parasites and characterising their glycoprotein structures, Rupa Nagar has been developing new mass spectrometry based (GC-MS and LC-MS) analytical methods to more easily compare wild type and mutant glycoprotein structures. These will also be particularly useful to characterise the effects on glycosylphosphatidylinositol (GPI) structures caused by making mutants lacking novel GPI biosynthetic pathway components recently discovered by Zhe Ji using quantitative proteomics approaches.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 14

The more we understand about these parasite gene expression mechanisms, the better placed we will be to facilitate drug discovery in this area.

‘The VEX’ed Trypanosome’. The image shows what happens to trypanosome variant surface glycoprotein (VSG) expression when you knockdown the expression of the genes VEX1 and VEX2 which sustain and coordinate VSG monoallelic expression.

The image was a finalist in the Infectious Diseases Hub Photographic competition 2019.

Image courtesy of Dr Joana Faria.

Underpinning much of this work, and helping many other Centre teams, Michele Tinti processes data, develops databases and applies machine learning techniques to maximise discovery from our data. As an example, a recent publication by Michele and Lucia in Wellcome Open Research makes available a massive and searchable dataset of protein turnover rates in bloodstream form and procyclic form trypanosomes. This, along with our previously published protein complexes and cell cycle proteome databases, should greatly assist the entire trypanosome research community to understand the proteins and protein complexes they work on.

The Field Group explores how eukaryotes have evolved and diverged over time. Parasites are some of the most ancient eukaroytes. The Field group use trypanosomes to model the compartments, such as the nucleus, that are characteristic of eukaroytic cells. This research identifies proteins and processes that are different between trypanosomes and human cells. For example, the nuclear architecture of trypanosomes is dramatically different from the human nucleus. Interestingly, the structure plays pivotal roles beyond defining the shape of this organelle.

It also directly interacts with the parasite genome and is involved in gene expression. The Field lab uses genetics and proteomics to identify novel components of the nuclear architecture and discover how they contribute to the severity of parasite infections. Components that are unique to the parasite (not found in humans) and required for survival are great starting points for drug discovery.

Conservation and divergence at the nuclear envelope.

The major protein and nucleic acid complexes responsible for control of gene expression, nucleocytoplasmic transport, and regulation of nuclear architecture are shown. From Rout MP, Obado SO, Schenkman S, Field MC (2017) Specialising the parasite nucleus: Pores, lamins, chromatin, and diversity.

PLoS Pathog 13(3): e1006170.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 15

New challenges

Cryptosporidiosis

The Pawlowic group are: (back row L to R) Stephen Andrews (Honours student), Jack Hanna, Ross Bacchetti, Senyo Botchie (visiting WCAIR Trainee); (front row L to R) Emma Sands, Mattie Pawlowic, Beatrice Colon and Lee Robinson (not pictured).

Cryptosporidium is a single cell parasite that causes diarrheal disease, for which there is no vaccine.

The only drug that exists to treat cryptosporidiosis isn’t effective in the patients most at risk. These patients are children under the age of 5, especially if they are malnourished, and immunocompromised adults. We use genetic and biochemical tools to better understand transmission of these important parasites and to create new methods to impact drug discovery.

Cryptosporidium are transmitted as an ‘oocyst’.

This form of the parasite is egg-like with a robust, protective shell. Cryptosporidium oocysts are waterborne and most water treatment methods, including chlorination (i.e. bleach), fail to kill Cryptosporidium. By understanding how the protective oocyst wall is constructed, we hope to discover new approaches to interrupt transmission.

The composition and construction of this the oocyst wall structure is largely unknown and understudied.

We are using cutting edge proteomics and mass spectrometry to create the first complete list of oocyst-related genes. Then using genetic tools, including CRISPR and knockdown strategies, we are determining which components are essential for parasite transmission. We are also creating new tools, reagents, and knowledge about parasite biology that will advance this emerging field.

An improved understanding of oocyst biogenesis and transmission will deliver the understanding of Cryptosporidium biology that is critical to identifying new targets for therapeutics, transmission-limiting vaccines, and interventions.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 16

We work in collaboration with the Drug Discovery Unit to find new medicines for cryptosporidiosis.

We have engineered new genetically modified Cryptosporidium reporter strains for high-throughput screening that expand the amount of information we can collect from our phenotypic screens. This will provide insight into how compounds work at a very early stage of drug discovery. We are incorporating organoid co-culture methods that produce continuous culture for Cryptosporidium. In vitro continuous culture of Cryptosporidium will greatly advance drug discovery assays with a greater window into both the parasite life cycle and a more realistic host environment.

We are collaborating with the Mode of Action group to build new technologies to understand how medicines work. Genetics tools are critical to validate drug targets. Target validation is key to advancing the pipeline of effective compounds closer to the clinic.

The image shows a histology section of a gut infected with Cryptosporidium (DNA blue, Crypto green, brush border of gut epithelium in red)

Mode of Action The development of new drugs to treat kinetoplastids and many other parasitic and infectious diseases has been hampered by a severe lack of robustly validated drug targets.

This has left drug discovery programs heavily reliant upon phenotypic screening in which large compound libraries are screened directly against parasites to identify suitable chemical start points, ‘hits’. This provides direct evidence of compounds that are known to kill or hinder growth of parasites. However, the downstream development and optimisation of these phenotypically active compounds are often hindered by lack of information regarding mechanism(s) of action and/or molecular target(s).

Specifically, knowledge of molecular targets is often crucial in developing strategies to overcome issues such as poor pharmacokinetics and toxicity. When the targets of active compounds are identified this information can then be used to support target-based and structure-enabled drug discovery programmes. Thus, mode of action studies can effectively integrate these two major, often disconnected, approaches to drug discovery.

The Mode of Action (MoA) group, led by Dr Susan Wyllie, was established 5 years ago to specifically focus on determining the MoA and/or molecular targets of compounds that are active against kinetoplastid parasites.

The group has developed a unique approach to MoA studies, using a matrix of new and established methods in the fields of high throughput genetics, cell biology and chemical proteomics. This multidisciplinary approach to drug target deconvolution has proven extremely effective, with the molecular targets of 24 compound series (including 4 pre-clinical candidates) identified to date.

Information emanating from these MoA studies has been invaluable in guiding multiple anti-kinetoplastid drug discovery programmes. For example, novel drug targets have been exploited using structure-based approaches and new target-based screens, compounds that act via mechanisms unsuitable for drug development have been de-prioritised, and diverse chemical series have been identified that inhibit a particularly promiscuous molecular target. The team now effectively underpins the drug discovery programmes within WCAIR and also works with multiple academic groups from around the world and key stakeholders in neglected tropical diseases drug discovery.

Capitalising on their experience in kinetoplastids and supported by a pump-priming grant from WCAIR, the team is now applying its multidisciplinary approach to support drug target deconvolution in other parasites, in particular Plasmodium, the parasite responsible for malaria. As a result of these studies, they have now been invited to join the prestigious the Bill and Melinda Gates Foundation funded “Malaria Drug Accelerator” consortium (MALDA).

Phenotypic Hits

[High througput] Genetics

Cell Biology & Biochemical Assays

[Chemical] Proteomics

RNai library (KD) Overexpression libraries (OE) RES generation/WGS

Morphology Cell cycle (FACS) Reporter cell lines

SILAC TPP Drug-bead pulldown

Target validation Chemically validated targets

Drug Discovery Programmes

Chemical Tools for Biology

The MoA team shares a lab with the groups of David Horn, Mark Field and Mike Ferguson, fostering the close collaboration between the groups, sharing ideas and methods. The genetic tools created by the groups to probe the biology of parasites can now be used to uncover the molecular targets of novel compounds.

Their high throughput ‘loss-of-function’ approach, screening millions of parasites, each with a different protein depleted, has been used to rapidly screen for drug resistance. This approach has recently facilitated the deprioritisation of compounds with toxicity issues, the identification of a new priority drug-target and new resistance mechanisms for anti-leishmanial drugs and the identification of a novel pro-drug activation mechanism.

The success of the loss-of-function approach prompted the development of new high-throughput gain-of-function screen. In T. brucei parasites, screening led by Richard Wall delivered identification of cleavage and polyadenylation specificity factor as the target of both the veterinary and clinical benzoxoboroles; the latter are in Phase II/III clinical trials against sleeping sickness. In Leishmania, screening confirmed that compounds designed to inhibit N-myristoyltransferase specifically engaged with the target within parasites.

CRISPR Cas9-based approaches have revolutionised biotechnology by allowing RNA-programmed targeting of specific chromosomal loci. Eva Rico developed efficient and inducible Cas9-based editing for T. brucei, and we made our new reagents available to the research community (http://www.addgene.org/David_Horn/).

Eva has continued the tool development and optimization process. Julie Kovářová used the approach for rapid gene knock-out and Eva used Cas9 to precision base-edit a drug binding pocket in a key drug-target.

We aim to address the limitations that remain in our current and future work. We will develop new tools for editing, gene-tagging, gene knock-out and more. We envision routine, and high-throughput use of these tools in multiple trypanosomatids by the drug discovery and wider research communities.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 17

Enhancing the pipeline for target-based screening

X-ray crystallography: image shows where the protein cystals are mounted within the Rigaku M007HF X-ray generator

Fragment libraries At WCAIR we are investing in structure driven drug discovery. This is leading us to curate new libraries based around low molecular weight compounds. These fragment or fragment-like libraries provide the ideal starting point for target-based screens using X–ray crystallography and NMR. The fragment libraries have several advantages over traditional compound libraries used in high throughput screening.

The simplicity of fragments compared to larger ‘drug-like’ compounds means a wide diversity of chemical space can be sampled efficiently with a few thousand diverse fragments. This allows us to screen far fewer molecules to identify multiple possible binding sites on the target protein and establish whether it is possible to find compounds that bind the target (ligandability assessment).

The optimisation of fragments tends to lead to novel molecules which would not otherwise be available.

One of the fragment library approaches that WCAIR is developing is based on covalent modifiers. Covalent modifiers are compounds that successfully stop the function of their target by permanently binding to it. They are often avoided in drug discovery due to concerns that reactive functional groups within the molecules may lead to organ toxicity, yet there are many approved medicines that work by covalently modifying their target. About one-third of the approved covalent medicines are for infectious diseases. WCAIR is interested in covalent modification because the mechanism of action can lead to favourable properties for an anti-infective medicine.

For example, the medicines should carry on working for a

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 18

long time after the medicine has been removed from the body of the patient, reducing the number of pills a person takes in a day. As the medicine leads to permanent inhibition of the target it is also more difficult for the pathogen to develop resistance against the medicine, a key issue for infectious diseases. Covalent modifiers may also be useful to target proteins considered to be undruggable through non-covalent modifying approaches.

High throughput protein production and X-ray crystallography Using fragment libraries to screen thousands of chemical fragments against a potential drug target requires a high throughput methodology to produce the structural data showing fragments bound to the target protein in just a few hours. The WCAIR Molecular Interactions Team have worked with scientists at the Diamond Light Source, Harwell to adapt their XChem technology to the needs of the WCAIR screening programmes and establish it in Dundee.

The drivers for XChem are to work on a very small scale, carry out as many tasks as possible in parallel, use computers to automatically do all the note-taking, and use robotics to do most (but not quite all) of the intricate work. Crystals are grown in droplets of liquid of just a few hundred nanolitres, into which a specialist acoustic dispenser then deposits a few nanolitres of the chemical fragment being tested. They are then left for a several hours to allow the fragment to soak into the crystal. If, and only if, the fragment binds specifically to a site on the protein will we be able to see it in the final structures via X-ray crystallography.

Getting crystals ready for an X-ray diffraction experiment is the one part of the procedure that robotics cannot perform, and we have to rely on the skills of our protein crystallographers to do this. However, we have in place the ‘shifter’, a piece of equipment that makes this easier and significantly faster than standard manual harvesting.

Various software tools are then used to process the diffraction data collected, easing some of the load on the crystallographers as they search through the numerous datasets for the successful fragments. Decoding the X-ray patterns to show the fragment bound to the target requires the specialist knowledge of the WCAIR team of computational chemists.

XChem relies on being able to make and crystallise the target protein in a form that replicates the natural shape of the protein in the cell. In parallel with setting up the XChem screen, WCAIR is developing high throughput protein production methods. The methods and technologies under development allow us to test different ways of making the protein in parallel with the aim of finding a suitable construct as efficiently as possible. The best method is then scaled up to produce enough protein for the XChem screen and potentially other biophysical screening methods.

The results of XChem are just the starting point. The structures guide the chemists, both computational and medicinal, in how to build up the fragments into larger molecules with more interactions with the target protein. They should therefore bind the target at low concentrations, while building all the attributes of high quality drug candidates. Compounds identified through this route enter the design-make-test cycle as they progress from hits to leads to candidate drugs.

Agilent RapidFire® Drug targets for infectious diseases are often cellular enzymes, as inhibiting critical pathways the parasite or bacteria requires to survive and replicate should kill the infectious organism and halt the disease. To test our compounds as we move them through the drug design and development pathway we use in vitro assays to test the ability of a compound to inhibit the action of its target enzyme. These in vitro assays rely on a ‘reporter’ substance (often a change in colour or amount of fluorescent light produced) to show the potency of the compound. The reporters are themselves chemical compounds, so some of the compounds we are testing can interfere with the read out making the assay unreliable.

Therefore, we are now replacing reporter-based assays by developing assays to run on the Agilent RapidFire® instrument. The RapidFire® washes and prepares enzyme test samples very quickly (in seconds) for measuring using mass spectrometry, a technique that identifies individual molecules based on their mass and charge.

The quality of data and capacity – we can run more than 15,000 tests in an individual run – allows us to quickly understand whether a chemical we have made is on the road to being a useful medicine or needs further alteration to improve activity or selectivity.

The advantages of the RapidFire® are: > Increased sensitivity > Reduced enzyme consumption > Increase signal to background noise > No requirement for coupled assays > Cheaper than many commercial fluorescence assays

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 19

Innovations in chemistry To address the limited resources available for Neglected Tropical Diseases drug discovery, productivity must improve to minimise the time to achieve key project milestones or close projects throughout the pipeline. Key issues include spending disproportionate time making and purifying compounds for the majority of hit series from compound screens that ultimately fail, e.g. flat SAR, wrong mode of action, and the challenge during lead optimisation to achieve the full range of properties required of preclinical candidates in a single molecule. The required significant productivity advances can only be achieved through a radical overhaul of the design-make-test cycle.

Design

We are working with partners to improve our compound design capabilities. This runs from designing diversity for screening hit validation, through in silico virtual compound enumeration, to multi-parameter optimisation of leads. For example, we are developing the use of quantum mechanics and Frontier Molecular Orbital calculations to predict the binding affinities of fragments to target proteins, to improve optimisation of core scaffolds of series. Working from an optimised core has been shown to accelerate identification of clinical candidates.

As a longer term goal we will explore replacing high throughput biochemical screening, with high throughput fragment screening, such as XChem methodology, or virtual fragment screening. This will be followed by enhanced computational approaches to rapidly optimise fragment hits into leads, to accelerate projects, and reduce costs and the need to maintain large compound libraries. We are developing our use of machine learning algorithms to allow the selection of target compounds to cover chemical space efficiently, either to optimise activity, pharmacokinetics, physicochemical properties, or add the most information to modelling.

Make

To rapidly make these designed compounds we are revamping our chemistry workflow, from delivering reagents into reactions, to dispensing compounds into assays more effectively.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 20

This has involved incorporating our Compound Management Team, previously focused on delivering compounds into assays, into our synthetic methodologies development team.

We have established a broad range of synthetic conditions to make multiple compounds in parallel, including flow and plate-based chemistry (96 and 384 microtitre plate format).

To efficiently deliver multiple reagents into this chemistry, we have established the use of liquid handling robotics, e.g. Tecan Evo and Echo dispensing, and preformatted sets of reagent classes, e.g. amines, boronic acids etc. This allows chemistry optimisation and compound synthesis down to a microgram scale, saving reagents, intermediates, time and cost. In addition, we are establishing methods to introduce diverse functional groups into compounds from a common intermediate, either chemically or through biotransformations. To enable these developments, we are developing high throughput methods to cope with the increased synthetic throughput for purification, automated analysis of analytical data and formatting of final compounds.

Test

To speed up cycle times we have and are continuing to identify multiple synthetic reagents and solvents that are acceptable in a range of biochemical, biophysical and parasite assays, so synthesised compounds can be tested without purification to rapidly explore compound design. For example, several plate-based synthesis projects have produced hundreds of unpurified compounds and screened them against the parasite Trypanosome cruzi growing in culture, identifying key activity structure related hot spots and eliminating the needed to purify, analyse and format thousands of inactive compounds.

Compounds of interest can be purified or resynthesized for full characterisation. To date this approach has allowed the production of 1862 compounds from 2966 attempts in 159 days during 2019. We are focusing efforts on increasing the success rate of plate-based and array approaches.

The challenges of drug discovery for Chagas disease Part 1 Finding new ‘hits’ Chagas disease is caused by the parasite Trypanosoma cruzi (T. cruzi). To start the search for new potential medicines we have created a hit-discovery screening cascade. This is continuingly being optimised to increase our chances of identifying compound series that will be successful in animal models of Chagas disease and eventually patients. We respond to new understanding of parasite biology and benchmark our assays based on their ability to predict in vivo animal model and clinical outcomes. This process of “back-translation” is essential to assure we only deploy the most relevant assays and remove series with low chance of success as quickly as possible, saving valuable time and resources.

The screening cascade starts with a high throughput primary screen to allow us to quickly test thousands of compounds. This is a high-content automated microscopy screening assay for intracellular amastigotes.

It is not only identifies new hits but also flags up compounds with undesired toxicity against host cells.

It has a throughput of about 10,000 compounds per week. As many of the hits identified in this assay act through inhibition of CYP51, a mode of action invalidated in the clinic, we have implemented a biochemical assay for this target to rapidly triage out such compounds. throughput

high-throughput intracellular HCS assay

trypomastigote assay

strain panel

rate-of-kill assay

CYP51 assay

washout assay

Host cell infected with T. cruzi parasite (small red spots), including one putative persister parasite (coloured blue).

A valuable assay recently developed in WCAIR is our live-imaging rate-of-kill assay to determine how fast compounds can kill parasites. This helps to prioritise compounds and design animal models of disease dosing regimens. In our live assay we image intracellular parasites every few hours in a microscope that is housed inside an incubator. This provides much better time-resolution compared to existing rate-of-kill assays, where a plate has to be fixed for each timepoint and allows continuous tracking of a set cell population.

Research shows that different T. cruzi strains replicate at varying rates within human host cells. We have therefore implemented secondary intracellular assays to test the compounds against both fast and slow replicating strains of T. cruzi. We also assess if compounds can kill the non-replicative transmission form, the trypomastigote.

Over recent years it has become evident that there is a small population of T. cruzi parasites that is much less susceptible to drug treatment than the bulk population.

We see these parasites in our assays and animal models and refer to them as persister parasites. None of the assays described above can reliably detect effects on these parasites. We have therefore developed a two month long washout assay that can determine killing of these less susceptible forms. We treat cells and parasites with compounds for up to 16 days. Then compounds are removed, and we observe the cells for up to two months to assure that no viable parasites emerge. To date this assay provides the best in vitro predictor of the ability for a compound series to achieve sterile cure in an animal efficacy model. As such this assay is now a key gatekeeper before we move compounds into animal model studies.

Together, this suite of assays allows us to quickly remove compounds with a low chance of success and focus our efforts on moving the most promising series towards the clinic.

in vivo efficacy

physiological relevance Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 21

The challenges of drug discovery for Chagas disease Part 2

1 x 103

compound dosing

Immunosuppression

Ex-vivo imaging

T. cruzi CL brener-luc Balb/c

Typical timeline for chronic Chagas disease mouse model.

Blue arrows are imaging times. Images depict a fully curative treatment regimen.

Demonstrating efficacy in animal models Our disease model of choice to evaluate the efficacy of novel compounds is a non-invasive bioluminescent imaging (BLI) mouse model. This also allows us to better understand parasite dynamics (1). Importantly, it correctly translates the limited clinical data that exists for this disease: benznidazole delivering cure and posaconazole fully relapsing. Recently testing novel compounds and compound series has been frustrating.

Compounds which have proved potent against the parasites in our in vitro screening cascade and have excellent blood pharmacokinetics have failed to prevent disease relapse in our mouse model. The figure above shows an example timeline for treating the model. The absence of all fluorescence signal (no colour on top of the mice or organs) at the end of the treatment shows that all parasites have been killed as the signal comes from the parasites themselves. When compounds fail to prevent relapse, we see time points after treatment when the fluorescent signal appears to have disappeared but then with time after treatment it reappears.

The potential reasons for a new drug treatment to not deliver ‘cure’ in the disease model are: 1) Inability to kill all forms of the parasite i.e. ‘wrong’ mode of action. There is growing evidence that there are persister/dormant parasites, less susceptible to drug treatment. Our new wash-out assay described in part 1 should help identify these compounds but success in vitro is not always followed by success in vivo.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 22

2) Poor drug distribution properties to those sites where parasites reside. It is clear from the bioluminescent mouse model of disease that the parasites are highly mobile and extensively distributed throughout the body, potentially located in tissues and organs that create significant drug delivery challenges, such as immunopriviledged sites (testes, ovaries and brain) and large, poorly perfused tissues (visceral fat).

To better understand where the parasites reside, we are developing more sensitive assays than bioluminescent imaging. To allow us to detect single parasites within organs we are implementing a method which makes the organs ‘see-through’. CUBIC (Clear, Unobstructed Brain/Body Imaging Cocktail) uses detergents that allow preservation of fluorescent proteins expressed by transgenic parasites within a tissue or organ, so they will be easily visualised without the need to dissect and thus disrupt the sample.

Once the tissue or organ has been cleared components such as the cell nucleus or other cellular structures can be labelled to help the scientist identify where the parasites are located. Using specialist microscopy, such as confocal or light-sheet microscopy, a 3D image of the tissue or organ can be built.

Examples of mouse organs cleared with CUBIC. Clockwise from top left: spleen, heart, kidney and lung.

Once we know in which organs (and areas of these organs) the parasites are located in, we need to check we are getting the correct amount of compound to these locations. We can use MALDI-MS imaging to detect the free compound distribution within the organ. It is important in order to investigate uniformity of distribution.

Non-uniform drug distribution could still account for sub-therapeutic tissue levels where the parasites reside even though whole tissue drug free concentration would advise otherwise.

As example, the figure shows there is non-uniform distribution of this lead compound in brain, yet total brain homogenate analysis suggested sufficient brain-free exposure to deliver cure.

Better knowledge of parasite localisation and drug distribution requirements will contribute to a better understanding of the properties anti-Chagas compounds need to deliver full sterile cure in the model of disease.

Ion distribution image of compound overlaid onto the corresponding H&E image (from section adjacent to MALDI-MS section).

1 Lewis MD, Francisco AF, Taylor MC, Kelly JM. A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging. J Biomol Screen. 2015 Jan;20(1):36-43.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 23

Public Engagement Public engagement is, by definition, a two-way process. We believe it has the power to transform communities; this includes those in and around Dundee, across the world, and within the Centre itself. Over the past three years, we’ve engaged with a wide range of people in pursuit of this mission.

Science art Since the Centre’s inception, we have been collaborating with colleagues from Duncan of Jordanstone College of Art and Design.

We believe that combining artists and scientist has numerous benefits, helping each to see their own work differently. It also enables the public to discover our work from a new angle.

Para-site-seeing: Departure Lounge WCAIR’s first sci-art installation started as commission for Dundee’s NEoN festival in 2018. The initial work was created as a ‘travel blog that Leishmania would write’. Co-creators Jen Southern and Rod Dillion (University of Lancaster) then expanded the concept to be an immersive experience within LifeSpace, our science art research gallery. With a check-in desk, passports to stamp and simulated sand fly gut to travel in, the show aimed to bring the feeling of being on a journey to life.

Over 500 visitors travelled with us while Para-site-seeing was in LifeSpace. The installation also spent several months at Dundee Science Centre and there are plans to send the artwork on its own global journey.

Find out more at https://para-site-seeing.org/

Translations: from laboratory to print studio

Artwork for ‘Translations’ by Sandra Carvalho

WCAIR’s current LifeSpace exhibition is a collaboration with the Dundee Print Collective. Over the past 18 months, we have been working together to explore the differences and similarities between science and art. This conversation has now come to life in a colourful series of art works. Expanding beyond the Print Collective’s traditional paper-based work, these are sculptural pieces making use of acrylic. They celebrate the people and processes who make our science and art come to life. It is no exaggeration to say that the show has been made by researchers from DPC and artists from WCAIR. Artwork for ‘Translations’ by Irene Hallyburton

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 24

engagement

Embedding into local communities

True public engagement begins from a real audience need. In each case, we have made the decision to work with targeted groups for long-term benefits, rather than quicker engagements. While the latter might appear to give higher numbers of engagements, we believe that stronger links will help drive more societal change.

Stobswell Forum We have chosen to work with the Stobswell Forum as our local community. Each May they run a festival, Stobfest. In 2018 and 2019 we contributed activities to the Gala Day. Having now established trust with residents we are growing our links, helping them develop their communications and fundraising while providing richer content for their future events.

Medicine Maker badge In 2019 we launched our brand new ‘Medicine Maker’ badge, in partnership with Girlguiding Dundee. This researcher- and community-need led project saw a group of scientists create a large pack of activities. The badge has been a success, with 1,300 participants nationwide. More events are planned with Girlguiding Dundee.

The creation of the badge won the team ‘Project of the Year’ in the Brian Cox Prize for Excellence in Public Engagement with Research awarded at School of Life Sciences Review 2019.

Parasites: Battle for Survival WCAIR has joined with the National Museum of Scotland, Wellcome Centre for Integrative Parasitology and Edinburgh Infectious Diseases to stage an exhibition at the Museum. Parasites: Battle for Survival highlights the research currently taking place in Scotland, and across the globe, to eliminate 5 deadly diseases. Malaria, Guinea Worm, Sleeping Sickness, Schistosomiasis and Leishmaniasis affect 1 in 18 people in the world.

The exhibition was due to run from 6 Dec 2019–20 April 2020. It had received 36,850 visitors by March 2020 when the COVID-19 pandemic caused the museum to close.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 25

engagemen

Artwork for ‘Translations’ by John Post

Gamify, game your sci Given Dundee’s place in the world of gaming, we have always been interested in the potential of games. They allow people to explore science from yet another angle, having fun while discovering new things about the world. In partnership with DC Thomson we created Disease Lab, an app for mobile users.

We have also created 2 new game experiences for people to play with us in person, where we can have rich conversations. Heal the World is a large-scale board game where players have to save the world from a disease outbreak, becoming the pieces themselves. Meanwhile we have created Diagnosis: kidnapped, which is inspired by the escape room phenomenon. Players have to solve a series of clues to complete a drug discovery programme. In each of these cases, our evaluation has shown that players report discovering how collaborative science really is, as well as learning new facts and having a great time.

WCAIR Public Engagement Team: Ali Floyd (PE Manager) and Ailsa Mackintosh The School of Life Sciences holds a Gold Engage Watermark from the National Co-ordinating Centre for Public Engagement.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 26

Training The aim of the WCAIR training programme is to support capacity building for drug discovery in the low- and middle-income countries most affected by the diseases we research. Training has been split into three main categories – trainees coming to Dundee, short courses, and partnerships.

WCAIR Training team and trainees July 2019

WCAIR Trainees in Dundee Since January 2018, we have delivered 196 months of training in Chemistry, Biology, DMPK and Parasitology. This training has been delivered to 25 trainees, from 11 different countries.

Trainees programmes are custom designed, based on their pre-existing skillset and their research. While the trainees have access to all our labs and associated equipment, we are mindful that these will not be available to them at their home institute. Great care is taken to train them with techniques that will be applicable in their own institution and skills that they can pass onto colleagues.

We ensure that they have as rounded an experience as possible with the opportunity to learn about all aspects of drug discovery research. This is achieved through seminars, access to our undergraduate modules in drug discovery, and a drug discovery game where all trainees form a small biotech company and have to see through all aspects of the drug discovery process (regardless of their own research area).

To maintain links and help the trainees implement their new skills when they return to their home institutions, they can apply for small project grants (up to £30K) to continue collaborating with WCAIR.

The WCAIR Training Team: Suze Farrell (Training Manager), Sandra O’Neill (Biology), Lauren Webster and Andrew Cairns (Medicinal Chemistry), Ola Epemolu (DMPK).

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 27

trainin

Short Courses The numbers of trainees that we can take in Dundee is limited (around 9 at one time). Another way to help build capacity is running short courses, which allow us to train a larger audience.

In collaboration with the Wellcome Genome Campus, we have run the ‘Practical Aspects in Small Molecule Drug Discovery’ for over a decade. In 2019 we took the course to University of Cape Town where it was open to scientists from the African continent only. Places were funded, removing financial barriers for attendance. We delivered the course to 26 participants from 19 different institutes from 11 different countries. The next programme will be with the Institut Pasteur de Montevideo in Uruguay in December 2021.

Training is also in development for a workshop-based course in Brazil funded through a Newton award. This will be delivered to partners’ teams and focussed on the relationship between Chemistry and DMPK.

Partnerships Dialogue with our trainees has helped us understand where our support can make most of a difference in their home countries. With this in mind we are focusing our resources at a few strategic partnerships.

Ghana. We are focusing our efforts on Ghana as there are a number of institutes working in drug discovery, and they have some infrastructure in place already. Following visits in 2019, we are acting as a coordinator to bring interested institutes together to form a drug discovery hub.

The aim is not only to further science within Ghana, but also within the region as they have strong research links with groups in neighbouring countries e.g. Cameroon and Nigeria.

Malawi. There are strong links between Scotland and Malawi at a governmental level coordinated by the Scotland-Malawi Partnership. Wellcome also invest in research through the Malawi-Liverpool-Wellcome Trust Clinical Research Programme and the Wellcome Centre for Integrative Parasitology, University of Glasgow.

Our partnership with the College of Medicine, Blantyre compliments these existing projects.

We have delivered 2 weeks of intense practical training at the College for the last 2 years. A technician from the College worked with us for 6 months in Dundee, and he helped develop and deliver a training programme to his colleagues on plant extraction techniques. This series of workshops was designed to be delivered to MSc students and we hope to develop more sets of workshops around the drug discovery theme.

Brazil. We have had scientific collaborations in Brazil for a number of years so it is a natural choice within Latin America. Much of the support that Brazil needs is in terms of training rather than infrastructure. A recent Newton Fund (MRC-FAPESP) award is allowing us to work with 3–4 partner institutes in São Paulo state to develop short-course training and train more individuals in Dundee.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 28

WCAIR Management Board

Prof. Paul Wyatt FRSE, Director, Baxter Chair and Professor Drug Discovery

Prof. David Horn FRSE, Deputy Director, Professor of Parasite Molecular Biology

Dr Catharine Goddard, Centre Manager

Dr Julie Brady, Business Development Manager

Louise Burns, Finance Manager

Dr Manu De Rycker, Head of Translational Parsitology

Prof. Ian Gilbert, FRSE FRSC, Head of Medicinal Chemistry

Prof. David Gray, Head of Biology, Academic lead for PE

Prof. Alan Fairlamb CBE FLS FRSE FMedSci FRSB, Wellcome Principle fellow

Prof. Sir Mike Ferguson, CBE FRS FRSE FMedSci FRSB, Regius Professor Life Sciences

Prof. Mark Field,FRSB, Professor Cell Biology and Parasitology

Dr Mattie Pawlowic, Sir Henry Dale Fellow

Prof. Kevin Read, Head of DMPK, Academic lead for Training

Dr Susan Wyllie, Head of Mode of Action Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 29

Selected Publications

Researchers at WCAIR have contributed to 86 publications between April 2017- March 2020. A full list of publications can be found on our website, wcair.dundee.ac.uk.

2017

Bayliss T, Robinson DA, Smith VC, Brand S, McElroy SP, Torrie LS, et al. Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. J Med Chem. 2017;60(23):9790–806 Crozier TWM, Tinti M, Larance M, Lamond AI, Ferguson MAJ. Prediction of Protein Complexes in Trypanosoma brucei by Protein Correlation Profiling Mass Spectrometry and Machine Learning. Mol Cell Proteomics. 2017;16(12):2254–67.

Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, et al. Anti-trypanosomatid drug discovery: An ongoing challenge and a continuing need. Nat Rev Microbiol. 2017;15(4):217–31.

Hallyburton I, Grimaldi R, Woodland A, Baragaña B, Luksch T, Spinks D, et al. Screening a protein kinase inhibitor library against Plasmodium falciparum.

Malar J. 2017;16(1):446.

Heikamp K, Zuccotto F, Kiczun M, Ray P, Gilbert IH. Exhaustive sampling of the fragment space associated to a molecule leading to the generation of conserved fragments. Chem Biol Drug Des. 2017;91(3):655–67.

Jinnelov A, Ali L, Tinti M, Güther MLS, Ferguson MAJ. Single-subunit oligosaccharyltransferases of Trypanosoma brucei display different and predictable peptide acceptor specificities. J Biol Chem. 2017;292(49):20328–41.

Ray PC, Kiczun M, Huggett M, Lim A, Prati F, Gilbert IH, et al. Fragment library design, synthesis and expansion: nurturing a synthesis and training platform. Drug Discov Today. 2017;22(1):43–56.

Torrie LS, Brand S, Robinson DA, Ko EJ, Stojanovski L, Simeons FRC, et al. Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani. ACS Infect Dis. 2017;3(10).

2018

Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, et al. Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB. J Med Chem. 2018;61(15):6592–608.

De Rycker M, Baragaña B, Duce SL, Gilbert IH. Challenges and recent progress in drug discovery for tropical diseases. Nature [Internet].

2018;559 498-506.

Fairlamb, Alan H and Patterson S. Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis [Internet].

Vol. 25, Current Medicinal Chemistry. 2018. p. 1–20.

Fairlamb AH, Horn D. Melarsoprol Resistance in African Trypanosomiasis. Trends Parasitol. 2018 Apr 26.

Jeacock L, Faria J, Horn D. Codon usage bias controls mRNA and protein abundance in trypanosomatids. elife. 2018;7:e32496.

Kovářová J, Nagar R, Faria J, Ferguson MAJ, Barrett MP, Horn D. Gluconeogenesis using glycerol as a substrate in bloodstream-form Trypanosoma brucei. PLOS Pathog. 2018;14(12):e1007475.

Liu D, Albergante L, Newman TJ, Horn D. Faster growth with shorter antigens can explain a VSG hierarchy during African trypanosome infections: a feint attack by parasites. Sci Rep. 2018;8, 10922.

Luise N, Wyatt PG. Diversity-oriented synthesis of bicyclic fragments containing privileged azines. Bioorg Med Chem Lett. 2018;29(2):248–51.

MacLean LM, Thomas J, Lewis MD, Cotillo I, Gray DW, De Rycker M. Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery. PLoS Negl Trop Dis. 2018;12(7):e0006612.

Murugesan D, Ray PC, Bayliss T, Prosser GA, Harrison JR, Green K, et al. 2-Mercapto-quinazolinones as inhibitors of NDH-2 and Mycobacterium tuberculosis: Structure-activity relationships, mechanism of action and ADME characterization. ACS Infect Dis. 2018;acsinfecdis.7b00275.

Pinger J, Nesic D, Ali L, Aresta-Branco F, Lilic M, Chowdhury S, Kim HS, Verdi J, Raper J, Ferguson MAJ, Papavasiliou FN, Stebbins CE. African trypanosomes evade immune clearance by O-glycosylation of the VSG surface coat. Nature Microbiol 2018;3: 932-938 Prati F, Zuccotto F, Fletcher D, Convery MA, Fernandez-Menendez R, Bates R, et al. Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA. ChemMedChem. 2018;13(7):672–7.

Quintana JF, Canavate R, Pino D, Yamada K, Zhang N, Field MC. Adaptation and Therapeutic Exploitation of the Plasma Membrane of African Trypanosomes. Genes (Basel). 2018;1–17.

Rico E, Jeacock L, Kovářová J, Horn D. Inducible high-efficiency CRISPR-Cas9-targeted gene editing and precision base editing in African trypanosomes. Sci Rep. 2018;8(1):7960.

Thomas J, Baker N, Hutchinson S, Dominicus C, Trenaman A, Glover L, Alsford S, Horn D. Insights into antitrypanosomal drug mode-of- action from cytology-based profiling. PLoS Negl Trop Dis. 2018; 12(11):e0006980 Thomas MG, De Rycker M, Cotillo Torrejon I, Thomas J, Riley J, Spinks D, et al. 2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas’ disease. Bioorganic Med Chem Lett. 2018;28(18):3025–30.

Thomas MG, De Rycker M, Ajakane M, Albrecht S, Álvarez-Pedraglio AI, Boesche M, et al. Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. J Med Chem. 2018;0(0):null.

Venkatesh D, Zhang N, Zoltner M, del Pino RC, Field MC. Evolution of protein trafficking in kinetoplastid parasites: Complexity and pathogenesis.

Traffic. 2018;(June):803–12.

Wall RJ, Rico E, Lukac I, Zuccotto F, Elg S, Gilbert IH, et al. Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proc Natl Acad Sci. 2018;201807915.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 30

2018 Wall RJ, Moniz S, Thomas MG, Norval S, Ko E-J, Marco M, et al. Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals.

Antimicrob Agents Chemother. 2018;62(8):1–15.

Wyllie S, Thomas M, Patterson S, Crouch S, De Rycker M, Lowe R, et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature.

2018;560(7717):192–7.

Zhang N, Zoltner M, Leung K-F, Scullion P, Hutchinson S, del Pino RC, et al. Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. PLOS Pathog. 2018 Feb 9;14(2):e1006850.

Zoltner M, Krienitz N, Field MC, Kramer S. Comparative proteomics of the two T. brucei PABPs suggests that PABP2 controls bulk mRNA. PLoS Negl Trop Dis. 2018;12(7).

2019 Baragaña B, Forte B, Choi R, Nakazawa Hewitt S, Bueren-Calabuig JA, Pisco JP, et al. Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proc Natl Acad Sci. 2019 Mar 20;201814685.

Bandini G*, Damerow S*, Güther MSL, Mehlert A, Guo H, Beverley SM, Ferguson MAJF. An essential GDP-Fuc: β-D-Gal α-1,2-fucosyltransferase is located in the mitochondrion of Trypanosoma brucei. bioRxiv 726117; doi: https://doi.org/10.1101/726117 *contributed equally Boehm C, Field MC. Evolution of late steps in exocytosis: conservation and specialization of the exocyst complex [version 2; peer review: 3 approved].

Wellcome Open Res. 2019;4(112).

Corpas-Lopez V, Moniz S, Thomas M, Wall RJ, Torrie LS, Zander-Dinse D, et al. Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani. ACS Infect Dis. 2019 Jan 11;5(1):111–22.

De Rycker M, Horn D, Aldridge B, Amewu RK, Barry CE, Buckner FS, et al. Setting Our Sights on Infectious Diseases. ACS Infect Dis. 2019 Dec 6.

Ebenezer TE, Zoltner M, Burrell A, Nenarokova A, Novák Vanclová AMG, Prasad B, et al. Transcriptome, proteome and draft genome of Euglena gracilis.

BMC Biol. 2019;17(1):11.

Faria J, Glover L, Hutchinson S, Boehm C, Field MC, Horn D. Monoallelic expression and epigenetic inheritance sustained by a Trypanosoma brucei variant surface glycoprotein exclusion complex. Nat Commun. 2019;10(1):3023.

Glover L, Marques CA, Suska O, Horn D. Persistent DNA Damage Foci and DNA Replication with a Broken Chromosome in the African Trypanosome.

Burleigh B, editor. MBio. 2019 Aug 27;10(4):e01252-19.

Homeyer N, van Deursen R, Ochoa-Montaño B, Heikamp K, Ray P, Zuccotto F, et al. A platform for target prediction of phenotypic screening hit molecules. J Mol Graph Model. 2019;107485.

Luise N, Wyatt EW, Tarver GJ, Wyatt PG. A Continuous Flow Strategy for the Facile Synthesis and Elaboration of Semi-Saturated Heterobicyclic Fragments. European J Org Chem. 2019;1–10.

Martin JS, MacKenzie CJ, Fletcher D, Gilbert IH. Characterising covalent warhead reactivity. Bioorg Med Chem 2019;27(10):2066–74.

Norcross NR, Wilson C, Baragaña B, Hallyburton I, Osuna-Cabello M, Norval S, et al. Substituted aminoacetamides as novel leads for malaria.

ChemMedChem. 2019;14(14) 1329-1335 Pawlowic MC, Somepalli M, Sateriale A, Herbert GT, Gibson AR, Cuny GD, et al. Genetic ablation of purine salvage in Cryptosporidium parvum reveals nucleotide uptake from the host cell. Proc Natl Acad Sci. 2019 Oct 15;116(42):21160–21165.

Sateriale A, Pawlowic M, Vinayak S, Brooks C, Striepen B. Genetic Manipulation of Cryptosporidium parvum with CRISPR/Cas9. In: Mead JR, Arrowood MJ, editors. Cryptosporidium: Methods and Protocols. New York, NY: Springer New York; 2020. p. 219–28.

Tinti M, Güther MLS, Crozier TWM, Lamond AI, Ferguson MAJ. Proteome turnover in the bloodstream and procyclic forms of Trypanosoma brucei measured by quantitative proteomics [version 1; peer review: 3 approved]. Wellcome Open Res. 2019;4(152).

Torrie LS, Zuccotto F, Robinson DA, Gray DW, Gilbert IH, De Rycker M. Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase. PLoS One. 2019;14(5):1–16.

Trenaman A, Glover L, Hutchinson S, Horn D. A post-transcriptional respiratome regulon in trypanosomes. Nucleic Acids Res. 2019 Jul 26;47(13):7063–77.

Wyllie S, Brand S, Thomas M, De Rycker M, Chung C, Pena I, et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proc Natl Acad Sci. 2019 Apr 3;201820175.

Zmuda F, Sastry L, Shepherd SM, Jones D, Scott A, Craggs PD, et al. Identification of novel Trypanosoma cruzi proteasome inhibitors using a luminescence-based high-throughput screening assay. Antimicrob Agents Chemother. 2019 Jul 15;AAC.00309-19.

Zmuda F, Shepherd SM, Ferguson MAJ, Gray DW, Torrie LS, De Rycker M. Trypanosoma cruzi phosphomannomutase and guanosine diphosphate-mannose pyrophosphorylase ligandability assessment. Antimicrob Agents Chemother. 2019 Aug 12;AAC.01082-19.

2020 Harrison, J. R., Sarkar, S., Hampton, S., Riley, J., Stojanovski, L., Sahlberg, C., … Gilbert, I. H. (2020). Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease. Journal of Medicinal Chemistry, 63(6), 3066–3089.

Innes, E. A., Chalmers, R. M., Wells, B., & Pawlowic, M. C. (2020). A One Health Approach to Tackle Cryptosporidiosis. Trends in Parasitology, 36(3), 290–303.

Pedron, J., Boudot, C., Brossas, J.-Y., Pinault, E., Bourgeade-Delmas, S., Sournia-Saquet, A., … Verhaeghe, P. (2020). New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi. ACS Medicinal Chemistry Letters, 11(4), 464–472 Wall, R. J., Carvalho, S., Milne, R., Bueren-Calabuig, J. A., Moniz, S., Cantizani-Perez, J., … Wyllie, S. (2020). The Q(i) site of cytochrome b is a promiscuous drug target in Trypanosoma cruzi and Leishmania donovani. ACS Infectious Diseases, 6(3) 515-528 Wang, Q., Boshoff, H. I. M., Harrison, J. R., Ray, P. C., Green, S. R., Wyatt, P. G., & Barry, C. E. (2020). PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosis. Science, 367(6482), 1147–1151.

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 31

WCAIR Timeline

January and February 2018: WCAIR’s 1st Trainees arrive, Daiane and Luma from Brazil

2018 April 2018: DDU, GSK and DNDi sign agreement to collaborate on drug discovery for leishmaniasis and Chagas disease

May 2018: WCAIR researchers walk Cateran trail for charity

December 2017: Dr Mattie Pawlowic joins WCAIR

November 2017: WCAIR runs Street Food for the first time in Dundee Science Festival

October 2017: University of Dundee named as world centre for pharmaceutical innovation by Clarivate Analytics

January 2019: Prof. Mike Ferguson receives knighthood in New Year honours list

July 2018: DDU, GSK and Wellcome announce new pre-clinical candidate for visceral leishmaniasis

WCAIR Scientists win School of Life Sciences awards for public engagement

September 2018: WCAIR researchers use Mode of Action studies to identify new target for sleeping sickness

April 2017: WCAIR starts with £13.6 million funding from Wellcome

2017 Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 32

December 2018: Mattie Pawlowic awarded Sir Henry Dale fellowship

November 2018: Para-Site-Seeing has its 1st show as part of NEoN festival, Dundee October 2018: Mode of Action group win GSK ‘STOP’ award WCAIR Training team make 1st visit to College of Medicine, Blantyre, Malawi

2019

December 2019: Parasites: Battle for Survival exhibition opens at National Museum of Scotland

February 2019: WCAIR and Girlguiding Dundee launch Medicine Maker badge

March 2019: WCAIR hosts 4th meeting Infectious Diseases Research Initiative Scotland, IDRIS

April 2019: WCAIR help WGC run 1st overseas Practical Aspects Drug Discovery Course in South Africa Mattie Pawlowic awarded inaugural British Soc. Parasitology President’s Medal

November 2019: David Horn wins William Trager Award

September 2019: David Gray promoted to Professor of Translational Biology

July 2019: DDU Malaria Team win MMV Project of the year 2018.

January 2020: DDU receives $3 million from B&MGF for TB research and announces partner of IMI funded ERA4TB February 2020: WCAIR 2nd Life Space Show ‘Translations’ opens.

A collaboration with Dundee Print Collective

Susan Wyllie promoted to Principal Investigator in School of Life Sciences.

June 2019: WCAIR scientists take part in Parkinson’s UK Great Glen challenge raising over £1,500 May 2019: WCAIR PE team make a return visit to Stobswell Gala day WCAIR hosts its 1st International conference on NTDs ‘SOSID’ WCAIR and GSK declare 2nd pre-clinical candidate for visceral leishmaniasis WCAIR opens its 1st LifeSpace exhibition. Para-Site-Seeing: Departure Lounge created by Jen Southern and Rod Dillon

March 2020: Ian Gilbert elected Fellow of the Royal Society Edinburgh DDU receives $5.3 million from COVID-19 Therapeutics Accelerator (initiated by the Bill & Melinda Gates Foundation, Wellcome and Mastercard) to work on anti-coronaviral agents.

2020

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 33

WCAIR Global Partners University of Glasgow University of Edinburgh Moredun Institute University of West Scotland Imperial College, London LSHTM

Spain & Portugal GSK, Tres Cantos

Canada

Universidad Pablo de Olavide-CSIC, Seville

SGC, Toronto University of Alberta

University of Porto

USA University of Washington Seattle Children’s Research Institute UT Southwestern Tufts University Washington University St Louis AbbVie Novartis NITD Emeryville Takeda USA Hackensack Meridian Health

Colorado State Weill Cornell University

Ghana Noguchi Memorial Institute for Medical Research, University of Ghana

UCSD University of Vermont University of Georgia NIAID Thomas Jefferson University John Hopkins University of Arizona

Brazil Federal U Sāo Paolo Oswaldo Cruz Foundation Adolfo Lutz Foundation Sāo Paolo

Merck & Co

Eisai USA

TB Alliance

Eli Lilly

Gates Foundation MALDA

Uruguay Insititut Pasteur de Montevideo

Wellcome Centre for Anti-Infectives Research is funded by the Wellcome Trust award 203134/Z/16/Z. We also thank our other funders and partners who support research within WCAIR: Academy of Medical Sciences, Bill and Melinda Gates Foundation, Drugs for Neglected Diseases initiative (DNDi), GlaxoSmithKline plc (GSK), Medicines for Malaria Venture (MMV), Medical Research Council (MRC), National Institute of Health (NIH).

UK

WCAIR is a member of the Tuberculosis Drug Accelerator (TBDA), Structure-guided Drug Discovery Coalition (SDDC), Malaria Drug Accelerator (MALDA), IMI European Regimen Accelerator for Tuberculosis (ERA4TB) and IMI Corona Accelerated R&D in Europe (CARE).

University of Cambridge MRC LMG Cambridge Queen Mary College, London University of Oxford University of Cardiff University of East London

Central Europe Institut Pasteur

Helmholtz Institute

University of Antwerp

Czech Academy of Sciences, Institute of Parasitology

DNDi MMV Swiss Tropical and PHI Cellzome University of Kiel

Charles University, Prague Ludwig-MaximilliansUniversität University of Berne

Asia Takeda Bukwang WuXi AppTec

Australia Bio21 Melbourne Science & Biotech Institute, University of Melbourne The Australian National University Monash University

South Africa

Eskitis Institute, Griffith University

HBD, University of Cape Town Stellenbosch University

Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 35

International Scientific Advisory Board Dr Graeme Bilbe Chair Senior Advisory and previous Research and Development Director, DNDi Professor Mike Blackman Group leader, Division of Parasitology, Francis Crick institute and Professor of Molecular Microbiology, London School of Hygiene & Tropical Medicine Professor Simon Croft FRSB Professor of Parasitology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine Professor Paul Herrling Professor of Drug Discovery Science, University of Basel (emeritus) (Wellcome representative) Professor John Kelly Professor of Molecular Biology, Department of Infection, London School of Hygiene and Tropical Medicine Dr Paul Leeson FRSC Independent Medicinal Chemistry Consultant. Paul Leeson Consulting Ltd. Honorary Professor of Medicinal Chemistry, University of Nottingham Professor Meg Philips The Sam G. Winstead and F. Andrew Bell Distinguished Chair in Biochemistry and Chair of the Department of Biochemistry UT Southwestern Professor Julian Rayner Director Cambridge Institute for Medical Research , University of Cambridge Director Wellcome Genome Campus Connecting Science Steve Rees Vice President Discovery Biology, AstraZeneca. Chair of European Laboratory Research & Innovation Group (ELRIG) Dr Isabela Ribeiro Head of Dynamic Portfolio Unit, DNDi Professor Jason Swedlow Professor of Quantitative Cell Biology, School of Life Sciences, University of Dundee

Chemistry Scientific Advisory Board Professor Varinder Aggarwal Professor in Synthetic Chemistry, University of Bristol Professor Tim Cernak Assistant Professor of Medicinal Chemistry and Chemistry, University of Michigan Dr David Lathbury Astute Chemical Development Consulting Ltd Dr Paul Leeson Director at Paul Leeson Consulting Ltd Professor Adam Nelson Professor of Chemical Biology, University of Leeds Dr Steve Taylor Founding Director at Celbius Ltd

Public Engagement Advisory Board Dr Hazel Lambert Public Engagement with Research Manager, University of Edinburgh Dr Emily Scott-Dearing Museum and Science Communication consultant Pamela MacLean Teacher, Grove Academy, Dundee Lynne Short Councillor, Dundee City Council

Training Review Board 2020 Dr Rachel Berkson Education Manager, Wellcome Genome Campus Advanced Courses and Scientific Conferences Dr Jeremy Burrows Vice President, Head of Drug Discovery at MMV Dr Ben Perry Senior Discovery Manager – Open innovation at DNDi Professor Jean Ker National lead for Clinical Skills, NHS Education Scotland Professor Julian Rayner Director Cambridge Institute for Medical Research , University of Cambridge Director Wellcome Genome Campus Connecting Science Alastair Strickland GCRF Development Manager, Research and Innovation, University of Dundee

Acknowledgements A big thank you to BCDD Admin and Lab management teams, the SLS Stores team, the SLS postgraduate team and all other SLS core teams without whom all the activities of the Centre would not run so smoothly.

Peachsnaps photograpghy photography for photographs at Setting our Sights on infectious Diseases.

Erika Stevenson for phorographs of Para-Site-seeing: Departure Lounge.

Other photographs from members of WCAIR. Design and Layout: Emma Quinn Design Wellcome Centre for Anti-Infectives Research 3rd Year Report I page 36

The Hamilton machine at the Drug Discovery Unit, University of Dundee ŠSophie Gerrard.

Part of a series of photographs commissioned for an exhibition to mark the 10 year anniversary of the DDU.

Wellcome Centre for Anti-Infectives Research School of Life Sciences University of Dundee Dow Street Dundee DD1 5EH WCAIR@dundee.ac.uk www.wcair.dundee.ac.uk @WCAIRDundee